Saccharomyces boulardii is a non-pathogenic yeast that occurs naturally in the human digestive system and has been extensively studied for its probiotic properties. It was first isolated from the skin of lychee and mangosteen fruits in 1923. Since then, Saccharomyces boulardii has been used as a probiotic that offers a range of beneficial effects, including enhancing gut barrier function, eliminating harmful pathogens, producing antimicrobial peptides, stimulating the immune system, and suppressing inflammation. Its therapeutic applications are primarily focused on preventing and treating various gastrointestinal tract disorders, such as diarrhoea symptoms (1).
Those with a weakened immune system, digestive tract issues or yeast allergies should consult their healthcare practitioner before using this product.
Epigenetics probiotic Saccharomyces boulardii is produced in a vegan friendly and convenient delayed release capsule. Recommended daily dose is 1 serving per day taken after a meal, or as directed by a healthcare practitioner. This product is not intended to be used as an alternative to a varied diet.
||Amount per serving
||250 mg (5B CFU)
|Inulin (from Jerusalem artichoke)
† Percent Daily Reference Intakes (RI) not established.
INGREDIENTS: Saccharomyces boulardii, Organic Jerusalem artichoke tuber extract (Helianthus tuberosus), Delayed release vegetable capsule (Hydroxypropyl methylcellulose, Gellan gum).
Suitable for vegans
Research suggests that Saccharomyces boulardii may help to treat certain infections. Helicobacter pylori is a type of bacteria commonly found in the digestive tract of individuals, which can sometimes lead to indigestion and stomach ulcers. A study conducted in 2019 analysed data from 18 previous trials to investigate the efficacy of using a combination of Saccharomyces boulardii and antibiotics in treating this infection. The study found that this combination was more effective than using antibiotics alone in eradicating the bacteria. Additionally, those who took Saccharomyces boulardii experienced fewer side effects, such as diarrhoea and constipation, and were less likely to discontinue treatment than those who only took antibiotics (2).
Likewise, Saccharomyces boulardii has been shown to assist in anti-inflammatory protection by preventing the secretion of interleukin 8 in the gut during an E. coli infestation. This can lead to a reduction in the severity and toxicity of the bacterial invasion. Research has indicated that the presence of Saccharomyces boulardii does not decrease the number of adherent bacteria produced by E. coli, but rather reduces the number of intracellular bacteria by approximately 50%. Saccharomyces boulardii is therefore considered a valuable tool in combatting E. coli infections and reducing associated inflammation (3).
The addition of boulardii to the treatment of ulcerative colitis patients has found to be effective. In animal models of inflammatory bowel disease (IBD), the combination of Saccharomyces boulardii and doxycycline has been shown to induce remission and prevent relapses. Saccharomyces boulardii has also been found to reduce the infiltration of Th1 cells and inhibit proinflammatory cytokine production in mice with IBD, while suppressing colitis and decreasing tissue levels in rats. In mice with colitis, Saccharomyces boulardii has been shown to reduce inflammation and intestinal colonisation by Candida albicans. Furthermore, the addition of Saccharomyces boulardii to baseline therapy has been found to improve intestinal permeability and reduce the frequency of bowel movements in Crohn’s disease patients (4).
Moreover, a study conducted to evaluate the potential of Saccharomyces boulardii in managing urinary tract infections (UTI) in children. The study aimed to investigate the impact of Saccharomyces boulardii on faecal E. coli, a common cause of acute and recurrent urogenital infections. The study involved 24 children who were administered Saccharomyces boulardii once a day at a dose of 5 billion for 5 days. Following treatment, a significant reduction in E. coli and yeast colonies was observed in the stool sample, indicating that Saccharomyces boulardii may have a role in the management of UTI in children (5).
It is important for certain groups to exercise caution when taking Saccharomyces boulardii. Elderly individuals, people with digestive tract diseases and those with weakened immune systems should consult with their healthcare practitioner before taking Saccharomyces boulardii. Similarly, individuals with yeast allergies may be allergic to products containing Saccharomyces boulardii and should avoid using them to prevent allergic reactions (6).
Packaging: 60 capsules
Recommended daily dose, 1 serving taken after a meal.
Serving size: 1 capsule, Servings per container: 60
Store in a refrigerator out of reach and sight of children. Once opened, consume within 6 months.